WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/057281    International Application No.:    PCT/EP2012/070805
Publication Date: 25.04.2013 International Filing Date: 19.10.2012
C07K 16/28 (2006.01)
Applicants: TRANSGENE SA [FR/FR]; Bd Gonthier d'Andernach Parc d'innovation F-67405 Illkrich (FR)
Inventors: HAEGEL, Hélène; (FR).
HALLET, Rémy; (FR)
Agent: VOSSIUS & PARTNER (NO. 31); Siebertstraße 4 81675 München (DE)
Priority Data:
11306368.9 21.10.2011 EP
Abstract: front page image
(EN)The invention is generally directed to promoting Ml-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-IR in a patient by assessing the in vivo or in vitro activation of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-IR on a subject being treated.
(FR)L'invention concerne généralement le déclenchement d'une réponse immunitaire de type M1 (polarisation des macrophages M1) par administration d'un composé modulant l'activation des macrophages. Elle concerne l'utilisation d'un anticorps capable de se lier à CSF-IR pour moduler l'activation des macrophages. Elle concerne également des méthodes permettant d'évaluer chez un patient l'efficacité de dose d'un anticorps capable de se lier à CSF-IR, par évaluation in vivo ou in vitro de l'activation des macrophages. Elle concerne en outre un test compagnon et des dosages de post-traitement qui permettent d'évaluer sur un sujet en traitement l'effet d'un anticorps capable de se lier à CSF-IR.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)